Published in Women's Health Weekly, September 9th, 2010
"The results showed antiproliferative activity of the derivative with significantly lower toxicity (an LD50 value ca. 20 times higher than that of parent daunorubicin) and an ability to completely overcome the resistance of cancer cells to this drug in vitro. Cardiotoxicity determination using male mice treated with a single dose of 75% of the LD50 value indicated that the cardiotoxicity of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly